MaxCyte Inc (LSE:MXCT)
ÂŁ 2.85 -0.06 (-2.06%) Market Cap: 299.50 Mil Enterprise Value: 192.38 Mil PE Ratio: 0 PB Ratio: 1.72 GF Score: 78/100

MaxCyte Inc at Cowen Health Care Conference Transcript

Mar 07, 2023 / 04:10PM GMT
Release Date Price: ÂŁ3.7 (-5.13%)
Max Masucci
Cowen Inc. - Analyst

Well, good to see everybody. Thanks for coming. 43rd Annual TD Cowen Health Care Conference. And I'm Max Masucci, life science and diagnostic tools analyst here at TD Cowen. And we're very pleased to be joined by MaxCyte, market-leading non-viral cell engineering company and a critical enabler, in our opinion, of the cell therapy field.

And so next to me is the company's President and CEO, Doug Doerfler. So Doug, great to see you in person.

Doug Doerfler
MaxCyte, Inc. - President & CEO

Thanks, Max. You, too.

Max Masucci;Doug Doerfler
Cowen Inc. - Analyst;MaxCyte, Inc. -

So I'm not sure what the mix is in the crowd of those that are new to the MaxCyte story and those that are familiar. So why don't we start with a brief, if possible, overview of MaxCyte's business today compared to when you founded the company in 1998? And then just any key differentiating factors of your ExPERT non-viral cell engineering platform technologies.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot